Press Release: Novartis to acquire Xiidra(R), -2-
Werte in diesem Artikel
globally and we are finding innovative ways to expand access to our
latest treatments. About 105 000 people of more than 140 nationalities
work at Novartis around the world. Find out more at www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at
http://twitter.com/novartis
For Novartis multimedia content, please visit
www.novartis.com/news/media-library
For questions about the site or required registration, please contact
media.relations@novartis.com
References
[1] Novartis International AG. (2018). Novartis Q4 and FY 2018
Condensed Financial Report - Supplementary Data. Retrieved from:
https://www.novartis.com/sites/www.novartis.com/files/2019-01-financial-report-en.pdf.
[2] FDA. Xiidra (lifitegrast ophthalmic solution). Prescribing
information. Available at:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208073s000lbl.pdf.
Accessed April 25, 2019.
[3] Paulsen AJ, Cruickshanks KJ, Fischer ME, et al. Dry eye in the
beaver dam offspring study: prevalence, risk factors, and health-related
quality of life. Am J Ophthalmol. 2014;157(4):799-806.
doi:10.1016/j.ajo.2013.12.023.
[4] American Optometric Association. Dry Eye. Available at:
https://www.aoa.org/patients-and-public/eye-and-vision-problems/glossary-of-eye-and-vision-conditions/dry-eye#1.
Accessed April 25, 2019.
[5] Sheppard AL, Wolffsohn JS. Digital eye strain: prevalence,
measurement and amelioration. BMJ Open Ophthalmol. 2018;3(1):e000146.
doi:10.1136/bmjophth-2018-000146.
[6] Bradley JL, Özer Stillman I, Pivneva I, et al. Dry eye
disease ranking among common reasons for seeking eye care in a large US
claims database. Clin Ophthalmol. 2019;13:225-232.
doi:10.2147/OPTH.S188314.
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com
Amy Wolf Peter Zuest
Global Head Communications, Ophthalmology Novartis Global Media Relations
+41 61 696 58 94 (direct) +41 79 899 9812 (mobile)
+41 79 576 07 23 (mobile) peter.zuest@novartis.com
amy.wolf@novartis.com
Eric Althoff
Novartis US External Communications
+1 646 438 4335
eric.althoff@novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
Central North America
Samir Shah +41 61 324 7944 Richard Pulik +1 862 778-3275
Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 862 778-3258
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Media release (PDF): http://hugin.info/134323/R/2243879/885977.pdf
This announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Novartis International AG via Globenewswire
--- End of Message ---
Novartis International AG
P.O. Box Basel Switzerland
WKN: 904278;ISIN: CH0012005267;
http://www.novartis.com
(END) Dow Jones Newswires
May 08, 2019 18:20 ET (22:20 GMT)
Ausgewählte Hebelprodukte auf Novartis
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Novartis
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Novartis AG
Analysen zu Novartis AG
Datum | Rating | Analyst | |
---|---|---|---|
04.07.2025 | Novartis Buy | Deutsche Bank AG | |
03.07.2025 | Novartis Neutral | UBS AG | |
02.07.2025 | Novartis Neutral | Goldman Sachs Group Inc. | |
01.07.2025 | Novartis Neutral | UBS AG | |
19.06.2025 | Novartis Buy | Deutsche Bank AG |
Datum | Rating | Analyst | |
---|---|---|---|
04.07.2025 | Novartis Buy | Deutsche Bank AG | |
19.06.2025 | Novartis Buy | Deutsche Bank AG | |
09.06.2025 | Novartis Buy | Deutsche Bank AG | |
30.04.2025 | Novartis Buy | Deutsche Bank AG | |
30.04.2025 | Novartis Kaufen | DZ BANK |
Datum | Rating | Analyst | |
---|---|---|---|
03.07.2025 | Novartis Neutral | UBS AG | |
02.07.2025 | Novartis Neutral | Goldman Sachs Group Inc. | |
01.07.2025 | Novartis Neutral | UBS AG | |
16.06.2025 | Novartis Neutral | UBS AG | |
12.06.2025 | Novartis Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) |
Datum | Rating | Analyst | |
---|---|---|---|
21.11.2024 | Novartis Underweight | Barclays Capital | |
24.06.2024 | Novartis Underweight | Barclays Capital | |
23.04.2024 | Novartis Underweight | Barclays Capital | |
28.03.2024 | Novartis Underweight | Barclays Capital | |
06.02.2024 | Novartis Underweight | Barclays Capital |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novartis AG nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen